This week's pod has everything:1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea.3. The largest RCT in primary CNS lymphomaDownload the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm